Vyne Therapeutics Inc (VYNE NASDAQ) stock market data APIs
$0.5612
0.01(1.8%)
as of January 30, 2026
Try our APIs with
free plan!
Vyne Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Prev. Close
0.5612
Open
0.562
High
0.5641
Low
0.5502
52 wk Range
0.281-2.94
Market Cap
18 857 K
Shares Outstanding
33 286 K
Revenue
524 K
EPS
-0.17
Beta
1.955
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Vyne Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Vyne Therapeutics Inc data using free add-ons & libraries
Get Vyne Therapeutics Inc Fundamental Data
Vyne Therapeutics Inc Fundamental data includes:
- Net Revenue: 524 K
- EBITDA: -43 633 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.3
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Vyne Therapeutics Inc News
New
Halper Sadeh LLC Encourages FOLD, VYNE, HTBK, FMNB Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK, Dec. 20, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or bre...
BC-Most Active Stocks
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Agape ATP Corporation 231,897,9...
VYNE Therapeutics GAAP EPS of -$0.17 misses by $0.04, revenue of $0.2M beats by $0.1M
* VYNE Therapeutics press release [https://seekingalpha.com/pr/20296695-vyne-therapeutics-reports-2025-third-quarter-financial-results-and-provides-business-update] (VYNE [https://seekingalpha.com/s...
Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
New York, USA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight The vitiligo treatment...
Get Vyne Therapeutics Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
